Car T cells containing anti-CD33, anti-cll1, and at least one additional car anticd123 and / or anti

摘要

This disclosure is directed to the anti-CD33 chimeric antigen receptor (car); Anti cll1 car; Also provides a cell comprising anti CD123 and / or anti car FLT3 car.The cells described above can be used in the treatment of diseases such as acute myelocytic leukemia (AML).The cell can target multiple antigens specific to acute myelocytic leukemia (AML), delay the transition to the clinical stage and provide an improved therapeutic approach for AML treatment compared to conventional T-cell therapy in the initial clinical trial stage.